Adenosine analogs as possible differentiation-inducing agents against acute myeloid leukemia

Leukemia and Lymphoma

Volumn 34, Issue 3-4, 1999, Pages 261-271

  Niitsu, Nozomi ^a   Honma, Yoshio ^a  

^a SAITAMA CANCER CENTER   (Japan)

Author keywords

Acute myeloid leukemia; Adenosine analog; Ara A; Deoxycoformycin; Differentiation; Neplanocin A

Indexed keywords

ADENOSINE DEAMINASE INHIBITOR; ADENOSINE DERIVATIVE; ADENOSYLHOMOCYSTEINASE; ANTILEUKEMIC AGENT; CYTARABINE; DEOXYADENOSINE; NEPLANOCIN A; PENTOSTATIN; RETINOIC ACID; RETINOID; VIDARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; CELL DIFFERENTIATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; HUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN PHOSPHORYLATION; REVIEW; TUMOR DIFFERENTIATION;

EID: 0032817045     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199909050951     Document Type: Review

References (67)

1. Collins, S.J., Bodner, A., Ting, R. and Gallo, R.C. (1980). Induction of morphological and functional differentiation of human promyelocytic leukemia cells (HL-60) by compounds which induce differentiation of murine leukemia cells. Int. J. Cancer, 25, 213-218.
2. Bodner, A.J., Ting, R.C. and Gallo, R.C. (1981). Induction of differentiation of human promyelocytic leukemia cells (HL-60) by nucleosides and methotrexate. J. Natl. Cancer Inst., 67, 1025-1030.
3. Ishiguro, K., Schwartz, E.L. and Sartorelli, A.C. (1984). Characterization of the metabolic forms of 6-thioguanine responsible for cytotoxicity and induction of differentiation of HL-60 acute promyelocytic leukemia cells. J. Cell. Physiol., 121, 383-390.
4. Rowley, P.T, Ohlsson-Wilhelm, B.M., Farely, B.A. and LaBella, S. (1981). Inducers of erythroid differentiation of K562 human leukemia cells. Exp. Hematol., 9, 32-37.
5. Castaigne, S., Daniel, M.T., Tilly, H., Herait, P. and Degos, L. (1983). Does treatment with Ara-C in low dosage cause differentiation of leukemic cells? Blood 62, 85-91.
6. 3, cytosine arabinoside and α-interferon on bone marrow cells from patients with myelodysplastic syndromes. Leuk. Res., 13, 1113-1121.
7. Honma, Y., Ikuta, T., Kasukabe, T., Hozumi, M., Itoh, T. and Ogura, H. (1988). Inhibition of proliferation and induction of differentiation of human myeloid leukemia cells by novel nucleoside analogs. Anticancer Res., 8, 695-699.
8. Makishima, M., Honma, Y., Hozumi, M., Sampi, K., Hattori, M., Ishikawa, I., Ogura, H., Kawahara, N., Kanaiwa, T. and Motoyoshi, K. (1991). Induction of differentiation of human myeloid leukemia HL-60 cells by novel pyrimidine nucleoside analogs. Biochim. Biophys. Acta, 1094, 1-7.
9. Makishima, M., Honma, Y., Hozumi, M., Sampi, K., Hattori, M., Ishikawa, I., Ogura, H. and Motoyoshi, K. (1992). Effects of novel uracil analogs on proliferation and differentiation of human myeloid leukemia cells. Exp. Hematol., 20, 879-885.
10. 3. Exp. Hematol., 26, 198-206.
11. Gilbert, E.R., Anderson, F., Cohen, B., Pollana, B. and Mewissen, H.J. (1972). Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet, 2, 1067-1068.
12. Mitchell, B.S. and Kelley, W.N. (1980). Purinogenic immunodeficiency diseases: clinical features and molecular mechanisms. Ann. Intern. Med., 92, 826-832.
13. LePage, G.A., Khalig, A. and Gottlieb, J.A. (1973). Studies of 9-β-D-arabinofuranosyladenine in man. Drug Metab. Dispos., 1, 756-759.
14. Montgomery, J.A. (1982). Studies on the biologic activity of purine and pyrimidine analogs. Med. Res. Rev., 2, 271-308.
15. Brockman, R.W., Schabel, F.M.J. and Montgomery, J.A. (1977). Biologic activity of 9-β-D-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-β-D-arabinofuranosyladenine. Biochem. Pharmacol., 26, 2193-2196.
16. Keating, M.J. (1997). Clinical trials of the purine analogs in chronic lymphocytic leukemia. In Nucleoside Analogs in Cancer Therapy, edited by B.D. Cheson, M.J. Keating and W. Plunkett, pp. 201-226. New York: Marcel Dekker.
17. Saven, A. and Piro, L.D. (1997) Treatment of hairly cell leukemia with nucleoside analogs. In Nucleoside Analogs in Cancer Therapy, edited by B.D. Cheson, M.J. Keating and W. Plunkett, pp. 227-246. New York: Marcel Dekker.
18. Hiddemann, W. and Pott-Hoeck, C. (1997). Clinical trials with nucleoside analogs in lymphomas. In Nucleoside Analogs in Cancer Therapy, edited by B.D. Cheson, M.J. Keating and W. Plunkett, pp. 247-288. New York: Marcel Dekker.
19. Niitsu, N., Umeda, M. and Honma, Y. (1997). Induction of differentiation of human myeloid leukemia cells by 2′-deoxycoformycin in combination with 2′-deoxyadenosine. Biochem. Biophys. Res. Commun., 238, 100-106.
20. Matsumoto, M., Tihan, T. and Cory, J.C. (1990). Effect of ribonucleotide-reductase inhibitors on the growth of human colon-carcinoma HT29 cells in culture. Cancer Chemother. Pharmacol., 26, 323-329.
21. Hershfield, M.S. (1979). Apparent suicide inactivation of human lymphoblast S-adenosyl homocysteine hydrolase by 2′-deoxyadenosine and adenine arabinoside. J. Biol. Chem., 254, 22-25.
22. Yaginuma, S., Muto, N., Tsujino, M., Sudate, Y., Hayashi, M. and Otani, M. (1981). Studies on neplanocin A. New antitumor antibiotic I. Producing organism, isolation and characterization. J. Antibiot., 34, 359-366.
23. Glazer, R.I. and Knode, M.C. (1984). Neplanocin A. A cyclopentenyl analog of adenosine with specificity for inhibiting RNA methylation. J. Biol. Chem., 259, 12964-12969.
24. Zimmerman, T.P., Schmitges, C.J., Wolberg, G., Deeprose, R.D., Duncan, G.S., Cuatrecasas, P. and Elion, G.B. (1980). Modulation of cyclic AMP metabolism by S-adenosylhomocysteine and S-3-deazaadenosylhomocysteine in mouse lymphocytes. Proc. Natl. Acad. Sci. USA, 77, 5639-5643.
25. Liu, X., Kim, C.N., Yang, J., Jemmerson, R. and Wang, X. (1996). Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome c. Cell, 86, 147-157.
26. Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S.M., Ahmadt, M., Alnemri, E.S. and Wang, X. (1997). Cytochrome C and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell, 91, 479-489.
27. Dion, H.W., Woo, P.W.K. and Ryder, A. (1977). Isolation and properties of a vidarabine deaminase inhibitor, co-vidarabin. Ann. N. Y. Acad. Sci., 284, 21-29.
28. Smyth, J.F., Paine, R.M., Jackman, A.L., Harrap, K.R. Chassin, M.M., Adamson, R.H. and Johns, D.G. (1980). The clinical pharmacology of the adenosine deaminase inhibitor 2′-deoxycoformycin. Cancer Chemother. Pharmacol., 5, 93-101.
29. Kraut, E.H., Grever, M.R. and Bouroncle, B.A. (1994). Long-term follow-up of patients with hairy cell leukemia after treatment with 2′-deoxycoformycin. Blood, 84, 4061-4063.
30. Yamaguchi, K., Yul, L.S., Oda, T., Maeda, T., Ishii, Y., Fujita, M., Kagiyama, K., Nagai, S., Suzuki, K. and Takatsuki, K. (1986). Clinical consequences of 2′-deoxycoformycin treatment in patients with refractory adult T-cell leukaemia. Leuk. Res., 10, 989-993.
31. Blick, M., Lepe-Zuniga, J.L., Doig, R. and Quesada, J.R. (1990). Durable complete remissions after 2′-deoxycoformycin treatment in patients with hairy cell leukemia resistant to interferon alpha. Am. J. Hematol., 33, 205-209.
32. Foon, K.A., Rai, K.R. and Gale, R.P. (1990). Chronic lymphocytic leukemia: New insights into biology and therapy. Ann. Intern. Med., 113, 525-539.
33. Cassileth, P.A., Cheuvart, B., Speirs, A.S.D., Harrington, D.P., Cummings, F.J., Neiman, R.S., Bennett, J.M. and O'Connell, M.J. (1991). Pentostatin induces durable remissions in hairy cell leukemia. J. Clin. Oncol., 9, 243-246.
34. Kefford, R.F. and Fox, R.M. (1982). Purine deoxyribonucleoside toxicity in non-dividing human lymphoid cells. Cancer Res., 42, 324-330.
35. Earle, M.F. and Glazer, R.I. (1983). 2′-Deoxycoformycin toxicity in murine spleen lymphocytes. Mol. Pharmacol., 23, 165-170.
36. Carson, D.A., Wasson, D.B., Lakow, E. and Kamatani, N. (1982). Possible metabolic basis for the different immunodeficient states associated with genetic deficiencies of adenosine deaminase and purine nucleoside phosphorylase. Proc. Natl. Acad. Sci. USA, 79, 3848-3852.
37. Fox, R.M., Kefford, R.F., Tripp, E.H. and Taylor, I.W. (1981). G1-phase arrest of cultured human leukemic T-cells induced by deoxyadenosine. Cancer Res., 41, 5141-5150.
38. Fox, R.M., Tripp, E.H. and Taylor, I.W. (1984). Analytical DNA flow cytometric analysis of deoxyadenosine toxicity in cultured human leukemic lymphoblasts. Mol. Pharmacol., 26, 388-394.
39. Daddona, P. (1981). Human adenosine-deaminase properties and turnover in cultured T and B lymphoblast. J. Biol. Chem., 256, 12496-12501.
40. Carson, D.A., Kaye, J., Matsumoto, S., Seegmiller, J.E. and Thompson, L. (1979). Biochemical basis for the enhanced toxicity of deoxyribonucleotides toward malignant human T-cell lines. Proc. Natl. Acad. Sci. USA, 76, 2430-2433.
41. Miller, R.L., Admaczyk, D.L., Miller, W.H., Koszalka, G.W., Rideout, J.L., Beacham, L.M., Chao, E.Y., Haggerty, J.J., Krenitsky, T.A. and Elion, G.B. (1979). Adenosine kinase from rabbit liver. II. Substrate and inhibitor specificity. J. Biol. Chem., 254, 2346-2352.
42. Pilz, R.B., Huvar, I., Scheele, J.S., Van den Berghe, G. and Boss, G.R. (1997). A decrease in the intracellular guanosine 5′-triphosphate concentration is necessary for granulocytic differentiation of HL-60 cells, but growth cessation and differentiation are not associated with a change in the activation state of ras, the transforming principle of HL-60 cells. Cell Growth Differ., 8, 53-59.
43. Honma, Y., Kasukabe, T. and Hozumi, M. (1981). Decrease in phospholipid methylation during differentiation of cultured mouse myeloid leukemia cells. Biochim. Biophys. Acta, 664, 441-444.
44. Mizutani, Y., Masuoka, S., Imoto, M., Kamada, M. and Umezawa, K. (1995). Induction of erythroid differentiation in leukaemic K562 cells by an S-adenosylhomocysteine hydrolase inhibitor aristeromycin. Biochem. Biophys. Res. Commun., 207, 69-74.
45. Tsujino, M., Yaginuma, S.,Fujii, T., Hayano, K., Matsuda, T., Watanabe, T. and Abe, J. (1981). Neplanocins new antitumor agents biological activity. Curr. Chemother. Infect. Dis., 3, 1559-1561.
46. Niitsu, N., Yamamoto-Yamaguchi, Y., Kanatani, Y., Shuto, S., Matsuda, A., Umeda, M. and Honma, Y. (1997). Neplanocin A, a potent inhibitor of S-adenosylhomocysteine hydrolase, potentiates granulocytic differentiation of acute promyelocytic leukemia cells induced by all-trans retinoic acid. Exp. Hematol., 25, 1296-1303.
47. North, T.H. and Cohen, S.S. (1979). Arabinosylnucleoside and nucleotides in viral chemotherapy. Pharmacol. Ther., 4, 81-108.
48. Brink, J.J. and Lepage, G.A. (1964). Metabolic effects of 9-β-D-arabinosyl-purines in ascites tumor cells. Cancer Res., 24, 312-318.
49. Liliemark, J. and Juliusson, G. (1997). Pharmacokinetics of purine nucleoside analogs. In Nucleoside Analogs in Cancer Therapy, edited by B.D. Cheson, M.J. Keating and W. Plunkett, pp. 73-93. New York: Marel Dekker.
50. Tallman, M.S. and Hakimian, D. (1995). Purine nucleoside analogs: Emerging roles in indolent lymphoproliferative disorders. Blood, 86, 2463-2474.
51. O'Dwyer, P.J., Wagner, B., Leyland-Jones, B., Wittes, R.E., Cheson, B.D. and Hoth, D.F. (1988). 2′-Deoxycoformycin (pentostatin) for lymphoid malignancies. Rational development of an active new drug. Ann. Intern. Med., 108, 733-743.
52. Huang, M., Ye, Y., Chen, S., Chai, J., Lu, J., Lin, Z., Gu, L. and Wang, Z. (1988). Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood, 72, 567-572.
53. Castaigne, S., Chomienne, C., Daniel, M.T., Ballerini, P., Berger, R., Fenaux, P. and Degos, L. (1990). All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood, 76, 1704-1709.
54. Warrell, R.P. Jr., Frankel, S.R., Miller, W.H. Jr., Scheinberg, D.A. Itri, L.M., Hittelman, W.N., Vyas, R., Andreff, A., Tafudi, A., Jakuobowski, A., Gabrilove, J., Gordon, M. and Dmitrovsky, E. (1991). Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid). N. Engl. J. Med., 329, 177-189.
55. Miller, W.H., Kakizuka, A., Frankel, S.R., Warrell, R.P., Deblasio, A., Levine, K., Evans, R.M. and Dmitrovsky, E. (1992). Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor-α clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA, 89, 2694-2698.
56. Cornic, M., Delva, L., Guidez, F., Balitrand, N. and Degos, L. (1992). Induction of retinoic acid-binding protein in normal in normal and malignant human myeloid cells by retinoic acid in acute promyelocytic leukemia patients. Cancer Res., 52, 3329-3334.
57. Warrell, R. Jr. (1993). Retinoid resistance in acute promyelocytic leukemia: New mechanisms, strategies, and implications. Blood, 82, 1949-1953.
58. Asou, N., Adachi, K., Tamura, A., Kanamaru, S., Kageyama, S., Hiraoka, A., Omoto, E., Akiyama, H., Tsubaki, K., Saito, K., Kuriyama, K., Oh, H., Kitano, K., Miyawaki, S., Takeyama, K., Yamada, O., Nishikawa, K., Takahashi, M., Matsuda, S., Ohtake, S., Suzushima, H., Emi, N. and Ohno, R. (1998). Analysis of prognostic factors in new diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. J. Clin. Oncol., 16, 78-85.
59. Lanotte, M., Martin-Thouvenin, V., Najman, S., Balerini, P., Valensi, F. and Berger, R. (1991). NB4, a maturation inducible cell line with t(15:17) marker isolated from human acute promyelocytic leukemia (M3). Blood, 77, 1080-1086.
60. Kasukabe, T., Honma, Y., Hozumi, M., Suda, T. and Nishii, Y. (1987). Control of proliferating potential of myeloid leukemia cells during long-term treatment with vitamin D3 analogues and other differentiation inducers in combination with antileukemic drugs: In vitro and in vivo studies. Cancer Res., 47, 567-572.
61. Hozumi, M. and Waxman, S. (1991). Design of combination differentiation therapy. In The Status of Differentiation Therapy of Cancer, Vol. II, edited by S. Waxman, G.B. Rossi and F. Takaku, pp. 347-353. New York: Raven Press.
62. Chen, A., Licht, J.D., Wu, Y., Hellinger, N., Scher, W. and Waxman, S. (1994). Retinoic acid is required for and potentiates differentiation of acute promyelocytic leukemia cells by nonretinoid agents. Blood, 84, 2122-2129.
63. Honma, Y., Kasukabe, T. and Hozumi, M. (1978). Induction of lysozyme activity by adenosine 3′:5′cyclic monophosphate in cultured mouse myeloid leukemia cells. Biochem. Biophys. Res. Commun., 82, 1246-1250.
64. McCachren, S.S., Nichols, J., Kaufman, R.E. and Niedel, J.E. (1986). Dibutyryl cyclic adenosine monophosphate reduces expression of c-myc during HL-60 differentiation. Blood, 68, 412-416.
65. Tortora, G., Tagliaferri, P., Clair, T., Colamonici, O., Neckers, L.M., Robins, R.K. and Cho-Chung, Y.S. (1988). Site-selective cAMP analogs at micromolar concentrations induce growth arrest and differentiation of acute promyelocytic, chronic myelocytic, and acute lymphocytic human leukemia cell lines. Blood, 71, 230-233.
66. Linevsky, J., Cohen, M.B., Hartman, K.D., Knode, M.C. and Glazer, R.I. (1985). Effect of neplanocin A on differentiation, nucleic acid methylation, and c-myc mRNA expression in human promyelocytic leukemia cells. Mol. Pharmacol., 28, 45-50.
67. Gieseler, F., Meyer, P., Schiffmann, D. and Wilms, K. (1989). Granulocytic differentiation of HL-60 cells is not regulated by DNA de novo methylation. Blut, 58, 159-163.